Nov 6, 2026 6 min read The Long View Obesity and Metabolic

The Long View: Big Pharma’s Obesity Shopping Moves Beyond The Incretin

The independent late-stage incretins are well funded and can wait for their price. The next deals are for mechanisms that have yet to show they combine well with incretins.

Capsul Desk

A long supermarket aisle with mostly empty metal shelves, a few open blue cardboard boxes and scattered jars and tins remaining, and a shopper in a dark coat at the far end. — The shelf is thin, not empty. *Photo by* *John Cameron* on *Unsplash*

Share Share Share Email

Therapeutic Thursday: Cost Cutting For Pace Or For Profitability

More on this topic

A pile of assorted metal keys in silver and gold tones scattered across a red surface.

The Long View: Imcivree Outgrew Its Lock

Oct 9, 2026 Capsul Desk 5 min read members

Beam of blue-white light from a cluster of nine LEDs at lower right, cutting diagonally through smoke against a black background.

Trial Tuesday: Lilly Steals The Show In Milan

Oct 6, 2026 Manas Mishra 4 min read members

More from this edition

A pair of black-framed glasses resting on a laptop keyboard in front of blurred monitors showing code and video-editing software, with the screen sharp through the lenses.

The Long View: Big Pharma’s Obesity Shopping Moves Beyond The Incretin

Read next

Therapeutic Thursday: Cost Cutting For Pace Or For Profitability

More on this topic

The Long View: Imcivree Outgrew Its Lock

Trial Tuesday: Lilly Steals The Show In Milan

More from this edition

The Long View: When The First Reader Is A Machine

The Long View: The AI Mountain Has Rules

The Long View: The Science Works, But Can We Scale It?